ArticleStem cell research & therapy2014
Diabetes impairs the angiogenic potential of adipose-derived stem cells by selectively depleting cellular subpopulations.
Article in Stem cell research & therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04255004 (Autologous Peripheral Blood Mononuclear Cells for Limb Salvage in Diabetic Foot Patients With No-option Critical Limb Ischemia), which is not on this map. Cited by 96 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Autologous Peripheral Blood Mononuclear Cells for Limb Salvage in Diabetic Foot Patients With No-option Critical Limb Ischemia
Who cites it
96 citing papers in PubMed, 2 syntheses or guidelines pooled it, 176 citations in OpenAlex.
- The Use of Hematopoietic Stem Cells for Heart Failure: A Systematic Review.International journal of molecular sciences · 2024Pooled it
- Effectiveness of preconditioned adipose-derived mesenchymal stem cells with photobiomodulation for the treatment of diabetic foot ulcers: a systematic review.Lasers in medical science · 2022Pooled it
- Differences in adipose-derived stem cells from rats with various health statuses and their effects in diabetic rats with erectile dysfunction.Asian journal of andrology · 2026Article
- Autologous Cell Therapy for Chronic Limb Threatening Ischemia: Towards Personalized Medicine.Angiology · 2026Review
- The Evolution of Nerve-Sparing Radical Prostatectomy: Mechanisms of Injury, Economic Impact, and the Potential Value of Intraoperative Nerve Visualization.Journal of clinical medicine · 2026Review
- Nutritional Interventions to Optimize Orthobiologic Therapy Quality in Type 2 Diabetes Mellitus: Molecular Mechanisms and Clinical Framework: A Narrative Review.International journal of molecular sciences · 2026Review
- Gelatin Sponge-Embedded Adipose-Derived Stromal Cells Enable Allogeneic Application for Revascularization of Ischemic Wounds.International journal of molecular sciences · 2026Article
- CAP-CD56Bioactive materials · 2026Article
- Exploring Mesenchymal Stromal Cells as a Potential Therapy for Comorbid Osteoarthritis and Type 2 Diabetes Mellitus.Stem cells international · 2025Review
- The Immune-Centric Revolution Translated into Clinical Application: Peripheral Blood Mononuclear Cell (PBMNC) Therapy in Diabetic Patients with No-Option Critical Limb-Threatening Ischemia (NO-CLTI)-Rationale and Meta-Analysis of Observational Studies.Journal of clinical medicine · 2024Review
- Characterizing Fibroblast Heterogeneity in Diabetic Wounds Through Single-Cell RNA-Sequencing.Biomedicines · 2024Review
- Senescence in Adipose-Derived Stem Cells: Biological Mechanisms and Therapeutic Challenges.International journal of molecular sciences · 2024Review
- Mesenchymal stem cell therapy in diabetic foot ulcer: An updated comprehensive review.Health science reports · 2024Article
- Increasing adipocyte number and reducing adipocyte size: the role of retinoids in adipose tissue development and metabolism.Critical reviews in food science and nutrition · 2024Review
- Advancements in culture technology of adipose-derived stromal/stem cells: implications for diabetes and its complications.Frontiers in endocrinology · 2024Review
- Advances in stem cell therapy for diabetic foot.Frontiers in genetics · 2024Review
- Application of adipose-derived stem cells in ischemic heart disease: theory, potency, and advantage.Frontiers in cardiovascular medicine · 2024Review
- Single-cell transcriptomics identifies adipose tissue CD271Cell reports. Medicine · 2023Article
- Cell Therapy and Investigation of the Angiogenesis of Fibroblasts with Collagen Hydrogel on the Healing of Diabetic Wounds.Turkish journal of pharmaceutical sciences · 2023Article
- Tissue Sheet Engineered Using Human Umbilical Cord-Derived Mesenchymal Stem Cells Improves Diabetic Wound Healing.International journal of molecular sciences · 2022Article
36 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
14 authors at 1 institution in 1 country.
Funding
Abstract
introductionPathophysiologic changes associated with diabetes impair new blood vessel formation and wound healing. Mesenchymal stem cells derived from adipose tissue (ASCs) have been used clinically to promote healing, although it remains unclear whether diabetes impairs their functional and therapeutic capacity.
methodsIn this study, we examined the impact of diabetes on the murine ASC niche as well as on the potential of isolated cells to promote neovascularization in vitro and in vivo. A novel single-cell analytical approach was used to interrogate ASC heterogeneity and subpopulation dynamics in this pathologic setting.
resultsOur results demonstrate that diabetes alters the ASC niche in situ and that diabetic ASCs are compromised in their ability to establish a vascular network both in vitro and in vivo. Moreover, these diabetic cells were ineffective in promoting soft tissue neovascularization and wound healing. Single-cell transcriptional analysis identified a subpopulation of cells which was diminished in both type 1 and type 2 models of diabetes. These cells were characterized by the high expression of genes known to be important for new blood vessel growth.
conclusionsPerturbations in specific cellular subpopulations, visible only on a single-cell level, represent a previously unreported mechanism for the dysfunction of diabetic ASCs. These data suggest that the utility of autologous ASCs for cell-based therapies in patients with diabetes may be limited and that interventions to improve cell function before application are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.